Tirzepatide 60mg
High-concentration tirzepatide (60mg) lyophilized vial for research applications requiring larger reagent quantities or extended in-vitro protocols. Same dual GIP/GLP-1 receptor agonist compound as the 30mg listing; the higher concentration reduces reconstitution frequency. Tirzepatide is an acylated peptide agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor (GLP-1R). In experimental receptor systems it shows greater relative engagement of GIPR and biased signaling at GLP-1R, favoring cAMP generation over beta-arrestin recruitment, with less receptor internalization than native GLP-1. Its C20 fatty-diacid modification promotes albumin binding and prolonged in-vitro stability. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.
Select Option
2+ save 5% · 5+ save 10% · 10+ save 20%
- Free Priority shipping on US orders over $100
- Ships same day on orders before 2 PM MST
- Discreet, unmarked packaging
- Third-party tested to a 99%+ purity standard
Mechanism of Action
Identical mechanism to tirzepatide 30mg — dual GIP/GLP-1 receptor co-agonism with preferential GIPR binding affinity. See tirzepatide 30mg listing for full mechanistic details.
Properties
Molecular Weight
4813.45 Da
Half-Life
~5 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Shipping & Delivery
- Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
- US shipping from $5. Free Priority on orders $100+ (before discounts).
- Plain, unmarked packaging — no branding or product names on the outside.
- Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Quality & Testing
- Independently tested by accredited third-party laboratories.
- Held to a 99%+ purity standard.
- USA-based; dispatched from Phoenix, Arizona.
- Supplied strictly for in-vitro laboratory research — not for human use.
Batch test records are published to each product as they are completed.
Research Applications
References & Citations
(4)LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, Sloop KW, Loghin C, et al.
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard FS, Douros JD, Gabe MB, et al.
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun B, Willard FS, Feng D, et al.
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice (animal study)
Samms RJ, Christe ME, Collins KA, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.